June 12, 2018/Cancer

Robotic Partial Nephrectomy for Tumors that Invade Sinus Fat (Video)

Achieving local cancer control without radical nephrectomy

By Jihad Kaouk, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In this era of robotic surgery, indications for partial nephrectomy (PN) are being widened to more complex renal masses.

In this video, we provide technical hints for achieving local cancer control during transperitoneal robotic PN (RPN) for T3 tumors that invade the sinus fat.

Technique

Our refined robotic technique entails a thorough examination of preoperative imaging and intraoperative renal ultrasound. Excision of the tumor is planned in such a way to shift retraction to the sinus fat. Such retraction allows for delineation of the fat involved with the tumor versus normal sinus fat away from the tumor.

Advertisement

We base our enthusiasm for this technique on a study of masses that underwent RPN at our institution. Of the 1,497 renal masses, 512 were suspected to have sinus fat invasion (RENAL score 3 for nearness to the sinus). Of these, 69 (13.5 percent) had pT3a tumor involving sinus fat at final pathology, representing the analyzed cohort. Twenty-four robotic transperitoneal PN were performed by our refined technique described in this video and 45 PNs were performed by our standard institutional technique.

Overall positive surgical margin (PSM) rate for the analyzed cohort (69 patients) was 11.6 percent. In patients operated on by our standard technique, the PSM rate was higher (0 percent versus 17.8 percent, P = 0.031). We were able to practically eliminate positive margins by refining our technique (P = 0.031). In patients operated on with the revised robotic technique presented on this video, trifecta achievement (no positive margins, no complications and excellent kidney function) was even higher compared to the standard technique (54.2 percent versus 20 percent, P = 0.005).

Differences in PSMs were not reflected in early oncological outcomes. Retrospective analysis and limited follow-up represent study limitations.

Advertisement

Conclusion

With consistent experience in robotic surgery, optimal cancer control can be achieved with this customized robotic approach, especially in cases when tumors involve the renal sinus, which would otherwise require a radical nephrectomy.

Clinical fellow Juan Garisto, MD, and research fellow Riccardo Bertolo, MD, assisted in the production of this video.

Related Articles

Women's health physician
April 16, 2024/Cancer
Watching Out for Primary Ovarian Insufficiency

An underdiagnosed condition in patients with cancer

Fluorescent imaging during small bowel surgery
April 11, 2024/Cancer/Surgical Oncology
Fluorescence Imaging Augments Surgical Inspection and Palpation for Small Bowel Carcinoid Tumors

Study demonstrates superior visualization of occult primary lesions

microwave ablation of liver tumor
150-Watt, Single-Antenna Microwave Ablation System Demonstrates Safety and Efficacy

New device offers greater tumor control for malignant liver lesions

viral-induced cancer
April 3, 2024/Cancer
Mechanism of Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) May Serve as Clue to More Effective Treatment

Cleveland Clinic researchers discover what drives – and what may halt – virus-induced cancer

Dr. Mukherjee at Cleveland Clinic
April 1, 2024/Cancer/Blood Cancers
Many Patients with “Indolent” Systemic Mastocytosis Experience Rapid Decline and Lower Survival

First-ever U.S. population-level retrospective analysis reveals many patients with systemic mastocytosis need faster intervention

Cleveland Clinic physiatrist
March 22, 2024/Cancer/Innovations
The Vital Role of Oncology Rehabilitation (Podcast)

New program provides prehabilitation and rehabilitation services to help patients with cancer maintain and regain function

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Ad